Evercore ISI Group Initiates Coverage On Summit Therapeutics with Outperform Rating, Announces Price Target of $30

Benzinga · 03/12 11:31
Evercore ISI Group analyst Cory Kasimov initiates coverage on Summit Therapeutics (NASDAQ:SMMT) with a Outperform rating and announces Price Target of $30.